Harnessing the power of cell therapies to rapidly engineer safe, effective, accessible treatments
to improve patient outcomes in oncology and other indications — beginning with what we believe is the first outpatient CAR-T.Nexcella, Inc. a subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indi...
Harnessing the power of cell therapies to rapidly engineer safe, effective, accessible treatments
to improve patient outcomes in oncology and other indications — beginning with what we believe is the first outpatient CAR-T.Nexcella, Inc. a subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.